Phosphorex Technologies Highlighted at Nanomedicine and Drug Delivery Symposium (NanoDDS’19)
Matthew Wingate, Director of Process Development, Described how Phosphorex Accelerates Nanomedicine Development from Proof of Concept to Clinical Trials
Hopkinton, Mass., September 22, 2019 – At the 2019 Nanomedicine and Drug Delivery Symposium (NanoDDS), Matthew Wingate, Director of Process Development, highlighted the advantages Phosphorex offers to clients. To date, Phosphorex has helped 60 life sciences companies (including 16 large pharma and biotech) develop their products and has completed 35 preclinical and clinical projects collaborating with biopharma and academia.
A recent project in which Phosphorex developed protein-loaded particles for a novel cancer vaccine implant now in clinical trials was highlighted. The Phosphorex team successfully loaded a hard-to-formulate peptide API into a sustained release formulation and achieved target product profile, scaled to 50 grams. The project included formulation design and development, scale-up, GLP batch production and tech transfer to a GMP facility with GMP batch support.